|

Proactive Risk Evaluation for Cardiac Implantable Electronic Device Strategy Using AI-ECG

RECRUITINGN/ASponsored by National Defense Medical Center, Taiwan
Actively Recruiting
PhaseN/A
SponsorNational Defense Medical Center, Taiwan
Started2025-11-01
Est. completion2026-10-31
Eligibility
Age65 Years – 90 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07217236

Summary

The goal of this clinical trial is to learn whether an artificial intelligence-enhanced electrocardiogram (AI-ECG) strategy improves timely intervention of patients requiring cardiac implantable electronic devices (CIEDs), compared with standard clinical care.

Eligibility

Age: 65 Years – 90 YearsHealthy volunteers accepted
Inclusion Criteria:

* At least one 12-lead ECG within 1 year

Exclusion Criteria:

* Diagnosis of sick sinus syndrome
* Diagnosis of high-grade or complete atrioventricular block
* Diagnosis of ventricular tachycardia or ventricular fibrillation
* Post CIED implant
* Heart rate below 40 beats per minute by 12-lead ECG

Conditions4

Artificial Intelligence (AI)Cardiac Implantable Electrical DevicesConduction Disorder of the HeartHeart Disease

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.